PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
•2.1 Preface
•2.2 Preface
•2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
•Market ecosystem
•Market characteristics
•Market segmentation analysis

PART 04: MARKET SIZING
•Market definition
•Market sizing 2018
•Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS
•Bargaining power of buyers
•Bargaining power of suppliers
•Threat of new entrants
•Threat of substitutes
•Threat of rivalry
•Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT
•Market segmentation by product
•Comparison by product
•Antipsychotics - Market size and forecast 2018-2023
•Non-antipsychotics - Market size and forecast 2018-2023
•Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
•Geographic segmentation
•Geographic comparison
•North America - Market size and forecast 2018-2023
•Europe - Market size and forecast 2018-2023
•Asia - Market size and forecast 2018-2023
•ROW - Market size and forecast 2018-2023
•Key leading countries
•Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
•Market drivers
•Market challenges

PART 11: MARKET TRENDS
•Development of novel therapeutics
•Increasing strategic alliances
•Growing number of research studies to understand genetic root cause of
•Tourette’s syndrome

PART 12: VENDOR LANDSCAPE
•Overview
•Landscape disruption

PART 13: VENDOR ANALYSIS
•Vendors covered
•Vendor classification
•Market positioning of vendors
•AstraZeneca Plc
•Boehringer Ingelheim International GmbH
•Eli Lilly and Co.
•H. Lundbeck AS
•Johnson & Johnson Services Inc.
•Mylan NV
•Otsuka Holdings Co. Ltd.
•Pfizer Inc.
•Sun Pharmaceutical Industries Ltd.
•Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX
•Research methodology
•List of abbreviations
•Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Non-antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Non-antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AstraZeneca Plc - Vendor overview
Exhibit 49: AstraZeneca Plc - Business segments
Exhibit 50: AstraZeneca Plc - Organizational developments
Exhibit 51: AstraZeneca Plc - Geographic focus
Exhibit 52: AstraZeneca Plc - Key offerings
Exhibit 53: AstraZeneca Plc - Key customers
Exhibit 54: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 55: Boehringer Ingelheim International GmbH - Business segments
Exhibit 56: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 57: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 58: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 59: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 60: Boehringer Ingelheim International GmbH - Key customers
Exhibit 61: Eli Lilly and Co. - Vendor overview
Exhibit 62: Eli Lilly and Co. - Business segments
Exhibit 63: Eli Lilly and Co. - Organizational developments
Exhibit 64: Eli Lilly and Co. - Geographic focus
Exhibit 65: Eli Lilly and Co. - Segment focus
Exhibit 66: Eli Lilly and Co. - Key offerings
Exhibit 67: Eli Lilly and Co. - Key customers
Exhibit 68: H. Lundbeck AS - Vendor overview
Exhibit 69: H. Lundbeck AS - Business segments
Exhibit 70: H. Lundbeck AS - Organizational developments
Exhibit 71: H. Lundbeck AS - Geographic focus
Exhibit 72: H. Lundbeck AS - Key offerings
Exhibit 73: H. Lundbeck AS - Key customers
Exhibit 74: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 75: Johnson & Johnson Services Inc. - Business segments
Exhibit 76: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 77: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 78: Johnson & Johnson Services Inc. - Segment focus
Exhibit 79: Johnson & Johnson Services Inc. - Key offerings
Exhibit 80: Johnson & Johnson Services Inc. - Key customers
Exhibit 81: Mylan NV - Vendor overview
Exhibit 82: Mylan NV - Product segments
Exhibit 83: Mylan NV - Organizational developments
Exhibit 84: Mylan NV - Geographic focus
Exhibit 85: Mylan NV - Segment focus
Exhibit 86: Mylan NV - Key offerings
Exhibit 87: Mylan NV - Key customers
Exhibit 88: Otsuka Holdings Co. Ltd. - Vendor overview
Exhibit 89: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 90: Otsuka Holdings Co. Ltd. - Organizational developments
Exhibit 91: Otsuka Holdings Co. Ltd. - Geographic focus
Exhibit 92: Otsuka Holdings Co. Ltd. - Segment focus
Exhibit 93: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 94: Otsuka Holdings Co. Ltd. - Key customers
Exhibit 95: Pfizer Inc. - Vendor overview
Exhibit 96: Pfizer Inc. - Business segments
Exhibit 97: Pfizer Inc. - Organizational developments
Exhibit 98: Pfizer Inc. - Geographic focus
Exhibit 99: Pfizer Inc. - Segment focus
Exhibit 100: Pfizer Inc. - Key offerings
Exhibit 101: Pfizer Inc. - Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 114: Validation techniques employed for market sizing
Exhibit 115: Definition of market positioning of vendors

Companies Mentioned
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co.
• H. Lundbeck AS
• Johnson & Johnson Services Inc.
• Mylan NV
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.